NGM Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
NGM Biopharmaceuticals's earnings have been declining at an average annual rate of -35.7%, while the Pharmaceuticals industry saw earnings growing at 1.6% annually. Revenues have been declining at an average rate of 26.1% per year.
Key information
-35.7%
Earnings growth rate
-26.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -26.1% |
| Return on equity | -95.8% |
| Net Margin | -3,223.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06Revenue & Expenses Breakdown
How NGM Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -142 | 37 | 0 |
| 30 Sep 23 | 22 | -151 | 39 | 0 |
| 30 Jun 23 | 30 | -170 | 41 | -15 |
| 31 Mar 23 | 37 | -178 | 41 | 1 |
| 31 Dec 22 | 55 | -163 | 41 | 0 |
| 30 Sep 22 | 58 | -153 | 40 | 0 |
| 30 Jun 22 | 69 | -135 | 39 | 80 |
| 31 Mar 22 | 77 | -125 | 39 | 1 |
| 31 Dec 21 | 78 | -120 | 37 | 0 |
| 30 Sep 21 | 77 | -121 | 35 | 0 |
| 30 Jun 21 | 82 | -122 | 32 | 0 |
| 31 Mar 21 | 85 | -111 | 29 | 4 |
| 31 Dec 20 | 87 | -102 | 27 | 0 |
| 30 Sep 20 | 99 | -90 | 26 | 0 |
| 30 Jun 20 | 97 | -72 | 25 | 0 |
| 31 Mar 20 | 102 | -54 | 25 | 0 |
| 31 Dec 19 | 104 | -43 | 24 | 0 |
| 30 Sep 19 | 120 | -13 | 22 | 0 |
| 30 Jun 19 | 119 | -9 | 22 | 0 |
| 31 Mar 19 | 116 | -5 | 19 | 0 |
| 31 Dec 18 | 109 | 0 | 17 | 0 |
| 30 Sep 18 | 81 | -17 | 16 | 0 |
| 30 Jun 18 | 80 | -12 | 15 | 0 |
| 31 Mar 18 | 77 | -13 | 15 | 0 |
| 31 Dec 17 | 77 | -14 | 15 | 0 |
| 31 Dec 16 | 86 | -7 | 12 | 0 |
Quality Earnings: NGM is currently unprofitable.
Growing Profit Margin: NGM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NGM is unprofitable, and losses have increased over the past 5 years at a rate of 35.7% per year.
Accelerating Growth: Unable to compare NGM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NGM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: NGM has a negative Return on Equity (-95.79%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/05 20:39 |
| End of Day Share Price | 2024/04/05 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NGM Biopharmaceuticals, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Paul Choi | Goldman Sachs |